Genentech to restrict Avastin availability due to off-label use

10/11/2007 | Wall Street Journal, The · NYTimes.com

Genentech said it will halt the distribution of its cancer treatment Avastin to compounding pharmacies as more ophthalmologists recommend the drug's off-label use for wet age-related macular degeneration. The move is an attempt to promote Genentech's more-expensive eye drug Lucentis, which has lagged in sales, but Medicare says limiting distribution of the cancer drug could cost the system as much as $3 billion a year.

View Full Article in:

Wall Street Journal, The · NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations